정신분열증에 대한 새로운 약리학적 치료 접근법: 포스트 iclepertin 시대 탐색

Englisch 등(Thu,)이 이 질문을 연구했습니다.

www.synapsesocial.com/papers/69a75d7fc6e9836116a279b0 — DOI: https://doi.org/10.1007/s40263-025-01259-4

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations· 2020 · 59 citations
2. LB-102 for acute schizophrenia in adults: Results from the phase 2 clinical trial (NOVA1) with a focus on Negative Symptoms· 2026 · 1 citations
3. Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia· 2014 · 230 citations
4. The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity· 2008 · 2,300 citations
5. FDA approves first schizophrenia drug with new mechanism of action since 1950s· 2024 · 21 citations